After this session, participants will be able to:

• Discuss the pathophysiology of primary aldosteronism
• Describe the unrecognized spectrum of primary aldosteronism
• Review the most recent recommended clinical approach, screening, and diagnostic guidelines of primary aldosteronism

After this session, participants will be able to:

After this session, participants will be able to:

• Understand why ejection fraction (EF) alone is not enough to diagnose or classify heart failure.
• Recognize that heart failure has many different causes, not just one single diagnoses.
• Describe a step-by-step approach to diagnosing heart failure, including using history, tests, and imaging.
• Explain why getting the correct diagnoses matters and how it can lead to better more targeted treatment for patient.

After this session participants will be able to:

• Explain the history of cancer genetics and genetics principles
• Describe the process of oncology genetic counseling and genetic testing
• Discuss case examples to demonstrate the utility of hereditary cancer genetic testing and ethical nuances

After this session, participants will be able to:

• Review past and current methods in assessing kidney function and their drawbacks
• Discuss common challenges in kidney function assessment in patients with cancer
• Illustrate upcoming methods to more accurately assess kidney function and tools in development

AKI: When All That Filters is not Liquid Gold - Presented by Omar Osman, MD

Deciphering Hematuria: A Clinical Update - Presented by Pye Oo, MD 

After this session participants will be able to: 

After this session, participants will be able to:

• Review the diagnosis of asthma and co-morbid conditions that exacerbate asthma.
• Describe when and how to initiate treatment. 
• Explain how to manage exacerbations both with and without steroids.
• Discuss when to seek a pulmonology or allergy consult.
• Review spacer education and training,

After this session participants will be able to:

• Describe the elements used in evaluating ANCA-associated vasculitis
• Discuss the utility of ANCA in the diagnosis of ANCA-associated vasculitis
• Identify the treatment options used for remission induction of ANCA-associated vasculitis
• Outline the treatment options to maintain remission of ANCA-associated vasculitis

After this session, participants will be able to:

• Identify population who would benefit from HIV pre-exposure prophylaxis (PrEP)
• Discuss key differences in currently available PrEP options
• Identify population who would benefit from doxycycline for post-exposure prophylaxis (doxyPEP)
• Discuss practical considerations for prescribing doxyPEP

After this, participants will be able to:

• Diagnose smoldering myeloma and differentiate from other plasma cell dyscrasias
• Understand the pathophysiology and natural history of smoldering myeloma
• Risk stratify patients with smoldering myeloma
• Identify the patients who require early intervention vs. active surveillance